# Ever/Body

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ever-body

- Industry: Healthcare Specialists
- Headquarters: New York, US
- Website: www.everbody.com
- Total disclosed funding: $81M
- Latest round: Series C (Apr 5, 2022)
- Investors on record: 10

## About

Ever/Body, Inc. is a US-based company specializing in advanced cosmetic dermatology, providing high-quality aesthetic treatments like Botox, laser therapies, and body sculpting services to enhance physical appearance and address common skin concerns.Founded in 2018 and headquartered in New York, US, Ever/Body, Inc. focuses on non-invasive cosmetic dermatological services. The company was established by Inna Plumb, Karen Castelletti, and Kate Twist. As of April 2022, Ever/Body raised USD 40.000 mn in Series C funding led by Addition, with a total amount raised of USD 40.000 mn and a current valuation of USD 153.242 mn.Ever/Body specializes in expert-led cosmetic dermatology, offering a range of aesthetic treatments that include Botox, laser therapies, and facials. The core product offerings focus on non-invasive body sculpting technologies such as truSculpt iD and Emsculpt NEO, designed to enhance body contours and reduce fat. These services cater to a diverse client base looking to improve their physical appearance without surgical interventions. Ever/Body operates primarily in urban markets across the United States, focusing on areas with a high demand for cosmetic services.Ever/Body's revenue model revolves around direct-to-consumer transactions, primarily through service appointments for cosmetic treatments. Clients typically schedule appointments for the various services, often facilitated by promotional offers such as discounts for first-time customers. Payment options may include financing through partners like Affirm, allowing clients to manage costs effectively. The company offers promotions such as a complimentary deluxe sample of OSEA Body Scrub with the purchase of specific treatments, which enhances customer engagement and drives sales. Ever/Body's services, including its flagship offerings like truSculpt iD, are priced to reflect the premium nature of the treatments provided, targeting clients who prioritize quality aesthetic care.In April 2022, Ever/Body, Inc. raised USD 40.000 mn in Series C funding led by returning investor Addition, with participation from other investors including Gaingels, Tiger Global Management, ACME Capital, Declaration Capital, Fifth Wall Ventures, and Redesign Health. The funding will be utilized to support national expansion, advancements in technology, and the acceleration of a proprietary education program for providers. The company aims to enhance its product offerings and expand into new markets, though specific details on product launches and targeted regions have yet to be disclosed.

## Funding rounds

- Series C, Apr 5, 2022, $40M — Tiger Global Management, ACME Capital, MetaProp, Gaingels, Fifth Wall Ventures, Imaginary Ventures, Declaration Capital, Addition, Redesign Health
- Series B, May 25, 2021, $24M — Tiger Global Management, ACME Capital, MetaProp, Gaingels, Fifth Wall Ventures, Declaration Partners, Addition, Redesign Health
- Series A, Sep 30, 2019, $17M — Tiger Global Management, ACME Capital, Declaration Partners, Redesign Health

## Investors

- Tiger Global Management (https://capitalatlas.ai/funds/tiger-global-management) — Series A, Series B, Series C
- ACME Capital (https://capitalatlas.ai/funds/acme-capital) — Series A, Series B, Series C
- Declaration Partners (https://capitalatlas.ai/funds/declaration-partners) — Series A, Series B
- Redesign Health (https://capitalatlas.ai/funds/redesign-health) — Series A, Series B, Series C
- MetaProp (https://capitalatlas.ai/funds/metaprop) — Series B, Series C
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series B, Series C
- Fifth Wall Ventures (https://capitalatlas.ai/funds/fifth-wall-ventures) — Series B, Series C
- Addition (https://capitalatlas.ai/funds/addition) — Series B, Series C
- Imaginary Ventures (https://capitalatlas.ai/funds/imaginary-ventures) — Series C
- Declaration Capital — Series C